JB Chemicals & Pharmaceuticals (JB Pharma), one of the fastest growing pharmaceutical companies in India, announced its financial results for the quarter and year ended 31st March, 2025.

Quarterly Financial Performance – Q4 FY25 vs Q4 FY24

JB Pharma recorded revenue of Rs. 949 crores in fourth quarter of FY25 registering growth of 10 per cent from Rs. 862 crores in Q4 FY24. Operating EBITDA (Earnings before Interest Depreciation and Taxes) improved by 15% to Rs. 240 crores in Q4 FY25 as compared to Rs. 210 crores in Q4 FY24. Profit after Taxes registered growth of 15 per cent to Rs. 146 crores in Q4 FY25 vs Rs. 126 crores in Q4 FY24.

Financial Performance –FY25 vs FY24

For the financial year 2024-25, the company recorded revenue of Rs. 3,918 crores as compared to Rs. 3,484 crores in FY23-24, registering growth of 12%. Operating EBITDA (Earnings Before Interest Depreciation and Taxes) increased by 16 per cent to Rs. 1,087 crores as compared to Rs. 939 crores. Profit after Tax registered growth of 19 per cent to Rs. 660 crores vs Rs. 553 crores in FY24.

Commenting on the financial results, Nikhil Chopra, CEO and Wholetime Director, JB Pharma mentioned, “We have closed the financial year FY25 on a strong note, in line with our strategic intent and sustained execution in the market. Our Domestic business continues to be one of the fastest growing in IPM. We have built a strong foundation over the last five years. With 75% of India branded formulations sales in progressive, faster-growing segments, we are confident in sustained strong performance going forward.

The CDMO business which is another focus area bounced back strongly in second half of the year. Together our Domestic and CDMO business now constitute 69% of overall revenues - Both businesses enjoy high ROCEs & high operating margins and contributed strongly towards enhancing profitability of the organisation.

Our outlook on growth is based on expansion within Domestic and CDMO businesses, as we have outlined consistently. A number of factors drive this growth include building on our existing brand franchises within India & executing key marquee projects in CDMO. We are confident therefore of charting superior growth and delivering improved profitability in the medium to longer term.”